Maybe they were getting everything lined up waiting for the FDARA to pass which it did last week. I believe any trials starting now will be under the new set of rules. I'm hoping several bios are set to explode.
I don't think so. I think it's more related to positioning around an EU partner and/or some sort of licencing, followed by EMA submission. If all of these events transpire, the valuation should land between 1.5 and 2 billion in short order.